Binaltorphimine

Binaltorphimine (also known as BNI) is a potent and selective antagonist for the kappa opioid receptor. It was originally derived from the opioid alkaloid nor-binaltorphimine. Binaltorphimine has been shown to produce antidepressant-like effects in animal studies.

Chemistry

Binaltorphimine is a derivative of the opioid alkaloid nor-binaltorphimine. It is a potent and selective antagonist for the kappa opioid receptor, with a high affinity for this receptor subtype. The chemical structure of binaltorphimine is characterized by a bis-quaternary structure, which is believed to contribute to its high potency and selectivity.

Pharmacology

Binaltorphimine acts as an antagonist at the kappa opioid receptor, meaning it blocks the action of kappa opioid agonists. It has a high affinity for the kappa opioid receptor, and a much lower affinity for the mu and delta opioid receptors. This selectivity makes binaltorphimine a useful tool in the study of the kappa opioid system.

Clinical significance

The kappa opioid system has been implicated in a number of physiological and pathological processes, including pain, mood disorders, and addiction. Binaltorphimine, as a kappa opioid antagonist, has potential therapeutic applications in these areas. In animal studies, binaltorphimine has been shown to produce antidepressant-like effects, suggesting a potential role in the treatment of depression.

See also

• Kappa opioid receptor
• Opioid antagonist
• Nor-binaltorphimine

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia